These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38940612)

  • 1. Improved anti-breast cancer activity by doxorubicin-loaded super stealth liposomes.
    Paolino D; d'Avanzo N; Canato E; Ciriolo L; Grigoletto A; Cristiano MC; Mancuso A; Celia C; Pasut G; Fresta M
    Biomater Sci; 2024 Jul; 12(15):3933-3946. PubMed ID: 38940612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy.
    Pasut G; Paolino D; Celia C; Mero A; Joseph AS; Wolfram J; Cosco D; Schiavon O; Shen H; Fresta M
    J Control Release; 2015 Feb; 199():106-13. PubMed ID: 25499917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
    Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
    Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
    Moosavian SA; Abnous K; Badiee A; Jaafari MR
    Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
    Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
    Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers.
    Guo Z; He B; Yuan L; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Int J Pharm; 2015 Sep; 493(1-2):380-9. PubMed ID: 26004003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid cell membranes camouflage liposomes containing payloads to improve breast cancer chemo and photodynamic therapy.
    Wang C; Wu S
    Biomater Sci; 2024 Sep; 12(19):4980-4992. PubMed ID: 39169828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surface-modified cationic liposomes with a matrix metalloproteinase-degradable polyethylene glycol derivative improved doxorubicin delivery in murine colon cancer.
    Askarizadeh A; Mashreghi M; Mirhadi E; Mehrabian A; Heravi Shargh V; Badiee A; Alavizadeh SH; Arabi L; Kamali H; Jaafari MR
    J Liposome Res; 2024 Jun; 34(2):221-238. PubMed ID: 37647288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin Nanoparticles Increase the Efficacy of Doxorubicin Hydrochloride Liposome Injection Based on Threshold Theory.
    Lin W; Li A; Qiu L; Huang H; Cui P; Wang J
    Mol Pharm; 2024 Jun; 21(6):2970-2980. PubMed ID: 38742943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrabilayer
    Luo D; Goel S; Liu HJ; Carter KA; Jiang D; Geng J; Kutyreff CJ; Engle JW; Huang WC; Shao S; Fang C; Cai W; Lovell JF
    ACS Nano; 2017 Dec; 11(12):12482-12491. PubMed ID: 29195037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
    Charrois GJ; Allen TM
    Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy.
    Cai D; Gao W; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2014 Feb; 35(7):2283-94. PubMed ID: 24360410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors.
    Ding Y; Cui W; Sun D; Wang GL; Hei Y; Meng S; Chen JH; Xie Y; Wang ZQ
    Drug Des Devel Ther; 2017; 11():3105-3117. PubMed ID: 29123382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of phospholipids with high transition temperature to enhance redox-sensitive liposomal doxorubicin efficacy in colon carcinoma model.
    Mirhadi E; Askarizadeh A; Farhoudi L; Mashreghi M; Behboodifar S; Alavizadeh SH; Arabi L; Jaafari MR
    Chem Phys Lipids; 2024 Jul; 261():105396. PubMed ID: 38621603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
    Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
    Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipopepsomes: A novel and robust family of nano-vesicles capable of highly efficient encapsulation and tumor-targeted delivery of doxorubicin hydrochloride in vivo.
    Qiu M; Sun H; Meng F; Cheng R; Zhang J; Deng C; Zhong Z
    J Control Release; 2018 Feb; 272():107-113. PubMed ID: 29355618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.